Weekly Fluorouracil at 425mg/m2 plus Low-dose Folinic Acid for 24 Weeks as Adjuvant Treatment for Colorectal Cancer: Assessment of Toxicity and Delivery

Ramani, V. S.; Gollins, Simon; Wong, Helen

doi:10.1016/j.clon.2006.08.005

Cited by 7 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data confirm the important role of treatment selection as one of the most important predictors of completion of adequate treatment with cytotoxic chemotherapy when geriatric patients are taken into consideration [39]. Regarding clinical parameters, PS showed a borderline effect on RDI while comorbidities did not [40,41,42,43].…”

Section: Discussionsupporting

confidence: 52%

Do Elderly Cancer Patients Achieve an Adequate Dose Intensity in Common Clinical Practice?

Luciani¹,

Marussi²,

Ascione³

et al. 2006

Oncology

View full text Add to dashboard Cite

Background: Elderly patients rarely receive adequate dose intensity (DI) using conventional regimens. Possible causes are improper patient assessment, the chemotherapy (CT) regimen chosen, the number and severity of comorbidities, patient compliance and physician experience. To explore this issue, DI was retrospectively analyzed in elderly patients treated with conventional CT regimens for advanced solid cancer. Patients and Methods: Patients ≧69 years were evaluated. All patients had metastatic solid tumors. Comorbidities, performance status (PS), toxicities, number of CT cycles, dose reduction and discontinuation of treatment were recorded. Relative DI (RDI) was calculated and regressed against these parameters. Results: 108 patients were eligible. The most frequent diagnoses were: lung, head-and-neck and colorectal cancer. In 48 patients (44%), their initially scheduled treatment was modified. Mean RDI was 79% (range 19–100%, SD 20.6). Grade 3/4 non-hematological and hematological toxicity occurred in 27 (35/130) and 8% of patients (11/130), respectively. In regression analysis, RDI was significantly associated with hematological toxicity. RDI affected response rate but not overall survival. Conclusions: RDI is significantly affected by toxicity. These data suggest the importance of the treatment schedule and patient selection as predictorsof adequate treatment. Some non-ratable variables, however, might also play a role regarding the dose intensity delivered.

show abstract

Section: Discussionsupporting

confidence: 52%

Do Elderly Cancer Patients Achieve an Adequate Dose Intensity in Common Clinical Practice?

Luciani¹,

Marussi²,

Ascione³

et al. 2006

Oncology

View full text Add to dashboard Cite

show abstract

“…23 Females experience worse toxicity than males following treatment for colorectal cancer. [24][25][26] Although not linked to pharmacodynamic measures, better outcomes for females have also been described for ES 27,28 and OS. 18,29 Gender-related difference in outcomes may be pharmacologic in origin, provided we accept that chemotherapy is critical to cure for these cancers.…”

Section: Discussionmentioning

confidence: 99%

Gender‐specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood

Khamly

Thursfield

Fay

et al. 2009

Intl Journal of Cancer

View full text Add to dashboard Cite

Good evidence indicates that adolescents and young adults (AYAs) with cancer do badly compared with children with similar cancers. The reasons are poorly understood. Australian registry data on 14,824 cancers of adolescence and young adulthood seen between 1982 and 2002 were reviewed. A detailed substudy of clinical characteristics was analyzed from 179 AYAs with Hodgkin lymphoma (HL), Ewing sarcoma (ES) or osteosarcomas (OS) treated at a single institution. Despite significant improvements in survival for both groups over the period in question, for acute lymphoblastic leukaemia, rhabdomyosarcoma, ES, OS and HL, survival for AYAs was worse than for children. For ES, OS and HL, the survival gap occurred almost entirely in males (Hazard ratios compared with female AYAs of 1.8 [p < 0.01], 1.4 [p = 0.03] and 1.5 [p < 0.01] respectively). Survival outcomes from ES, OS and HL for female AYAs were not significantly different from children of either sex. For brain tumors and thyroid cancers, which are primarily treated surgically, there were no gender‐related differences in outcomes. Although no differences in tumor stage or compliance were identified, male AYAs experienced less toxicity and lower response rates to chemotherapy (p = 0.008). Young males account almost entirely for excess mortality from chemosensitive cancers of adolescence and young adulthood compared to children, which may be due to relative underdosing with current chemotherapy dosing algorithms. © 2009 UICC

show abstract

“…10 Large studies in patients with breast cancer or non-Hodgkin lymphoma 15 used RDI measures and demonstrated that a low RDI was strongly associated with adverse patient outcomes. 13,16,17 In CRC, few data are available, and most come from small clinical series focused on patients with metastases and from clinical trials. A recent study assessed RDIs in 36 and 30 patients included in phase II trials of FOLFIRI and FOLFOX6 and found that low RDI was associated with adverse clinical outcomes.…”

mentioning

confidence: 99%

Chronological Age and Risk of Chemotherapy Nonfeasibility:

Laurent¹,

Guetz²,

Bastuji‐Garin³

et al. 2018

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

Weekly Fluorouracil at 425mg/m2 plus Low-dose Folinic Acid for 24 Weeks as Adjuvant Treatment for Colorectal Cancer: Assessment of Toxicity and Delivery

Cited by 7 publications

References 28 publications

Do Elderly Cancer Patients Achieve an Adequate Dose Intensity in Common Clinical Practice?

Do Elderly Cancer Patients Achieve an Adequate Dose Intensity in Common Clinical Practice?

Gender‐specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood

Chronological Age and Risk of Chemotherapy Nonfeasibility:

Contact Info

Product

Resources

About